Biodel Inc.(A Development Stage Company) Condensed Statements of Operations (in thousands, except share and per share amounts) (unaudited) | |||||||||||||||||||||
December 3, | |||||||||||||||||||||
2003 | |||||||||||||||||||||
Three Months Ended | Six Months Ended | (inception) to | |||||||||||||||||||
March 31, | March 31, | March 31, | |||||||||||||||||||
2010 | 2011 | 2010 | 2011 | 2011 | |||||||||||||||||
Revenue | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||||
Operating expenses: | |||||||||||||||||||||
Research and development | 7,014 | 2,902 | 15,768 | 8,408 | 124,636 | ||||||||||||||||
General and administrative | 3,377 | 2,305 | 5,793 | 4,882 | 52,507 | ||||||||||||||||
Total operating expenses | 10,391 | 5,207 | 21,561 | 13,290 | 177,143 | ||||||||||||||||
Other (income) and expense: | |||||||||||||||||||||
Interest and other income | (2) | (5) | (7) | (10) | (5,516) | ||||||||||||||||
Interest expense | — | — | — | — | 78 | ||||||||||||||||
Adjustments to fair value of common stock warrant liability | — | 237 | — | (2,535) | (1,281) | ||||||||||||||||
Loss on settlement of debt | — | — | — | 627 | |||||||||||||||||
Operating loss before tax provision (benefit) | (10,389) | (5,439) | (21,554) | (10,745) | (171,051) | ||||||||||||||||
Tax provision (benefit) | 20 | 3 | 3 | 6 | (606) | ||||||||||||||||
Net loss | (10,409) | (5,442) | (21,557) | (10,751) | (170,445) | ||||||||||||||||
Charge for accretion of beneficial conversion rights | — | — | — | — | (603) | ||||||||||||||||
Deemed dividend — warrants | — | — | — | — | (4,457) | ||||||||||||||||
Net loss applicable to common stockholders | $ | (10,409) | $ | (5,442) | $ | (21,557) | $ | (10,751) | $ | (175,505) | |||||||||||
Net loss per share — basic and diluted | $ | (0.44) | $ | (0.21) | $ | (0.90) | $ | (0.41) | |||||||||||||
Weighted average shares outstanding — basic and diluted | 23,885,856 | 26,469,890 | 23,867,152 | 26,444,219 | |||||||||||||||||
